← Shanghai ZJ Bio-Tech Co. Ltd. A overview

Shanghai ZJ Bio-Tech Co. Ltd. A vs Zhonghong Pulin Medical Products: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shanghai ZJ Bio-Tech Co. Ltd. A (688317.CG)

Q3 202620 Jul – 9 Oct 2026

▲2▼1

ZJ Bio-Tech: product approvals build pipeline, but losses widen

New product approvals expand addressable market ZJ Bio-Tech won three regulatory clearances: Vietnam certification for two products (July 20), a China Class III HPV genotyping kit (July 31), and a Class III monkeypox detection kit (Aug 19). These open new markets and enrich the product lineup, supporting future revenue growth.
These approvals are the main positive catalysts that could drive future sales and investor optimism.
Interim loss widens sharply on falling revenue First-half 2026 revenue fell 10.55% to 53.39 million yuan, while net loss widened to 40.59 million yuan from 9.85 million yuan a year earlier. Operating cash flow also dropped 55%. The weak financials weigh on the stock and raise doubts about near-term profitability.
The widening loss is the key fundamental negative that pressures the share price.
Company continues share buybacks ZJ Bio-Tech repurchased 5.51 million shares for 105 million yuan by Sept 30, up from 4.37 million shares in early August. Buybacks reduce shares outstanding and signal management confidence, offering some support to the stock price.
Buybacks are a capital action that can cushion the stock and show insider confidence.

August 202620 Jul – 9 Oct 2026

▲2▼1

ZJ Bio-Tech: product approvals build pipeline, but losses widen

New product approvals expand addressable market ZJ Bio-Tech won three regulatory clearances: Vietnam certification for two products (July 20), a China Class III HPV genotyping kit (July 31), and a Class III monkeypox detection kit (Aug 19). These open new markets and enrich the product lineup, supporting future revenue growth.
These approvals are the main positive catalysts that could drive future sales and investor optimism.
Interim loss widens sharply on falling revenue First-half 2026 revenue fell 10.55% to 53.39 million yuan, while net loss widened to 40.59 million yuan from 9.85 million yuan a year earlier. Operating cash flow also dropped 55%. The weak financials weigh on the stock and raise doubts about near-term profitability.
The widening loss is the key fundamental negative that pressures the share price.
Company continues share buybacks ZJ Bio-Tech repurchased 5.51 million shares for 105 million yuan by Sept 30, up from 4.37 million shares in early August. Buybacks reduce shares outstanding and signal management confidence, offering some support to the stock price.
Buybacks are a capital action that can cushion the stock and show insider confidence.

Latest20 Jul – 9 Oct 2026

▲2▼1

ZJ Bio-Tech: product approvals build pipeline, but losses widen

New product approvals expand addressable market ZJ Bio-Tech won three regulatory clearances: Vietnam certification for two products (July 20), a China Class III HPV genotyping kit (July 31), and a Class III monkeypox detection kit (Aug 19). These open new markets and enrich the product lineup, supporting future revenue growth.
These approvals are the main positive catalysts that could drive future sales and investor optimism.
Interim loss widens sharply on falling revenue First-half 2026 revenue fell 10.55% to 53.39 million yuan, while net loss widened to 40.59 million yuan from 9.85 million yuan a year earlier. Operating cash flow also dropped 55%. The weak financials weigh on the stock and raise doubts about near-term profitability.
The widening loss is the key fundamental negative that pressures the share price.
Company continues share buybacks ZJ Bio-Tech repurchased 5.51 million shares for 105 million yuan by Sept 30, up from 4.37 million shares in early August. Buybacks reduce shares outstanding and signal management confidence, offering some support to the stock price.
Buybacks are a capital action that can cushion the stock and show insider confidence.

Zhonghong Pulin Medical Products Co. Ltd. (300981.CS)

Q3 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

August 202628 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.

Latest28 Jul – 26 Aug 2026

▲3▼1

Glove Price Surge Drives Zhonghong Medical Profit Explosion

First-Half Profit Forecast Surges Over 23-Fold Zhonghong Medical expects first-half 2026 net profit of 140–210 million yuan, up 2,338%–3,557% year-on-year, driven by higher selling prices for health protection gloves and improved cost control. This signals a strong turnaround and boosts investor confidence, pushing the stock price up.
This is the core new event that directly explains the profit surge and its cause.
Actual First-Half Net Profit Jumps 26-Fold The semi-annual report confirmed net profit of 159 million yuan, up 2,662% year-on-year, with second-quarter profit alone at 154 million yuan. Revenue rose 19.46% to 1.478 billion yuan. This concrete result validates the earlier forecast and reinforces the positive price trend.
It provides the actual financial outcome, confirming the earlier forecast and strengthening the investment case.
Stock Price Rises Over 50% Since July As of August 25, the share price stood at 14.77 yuan, up more than 50% since July, with a market value of 6.3 billion yuan. This reflects the market's positive reaction to the profit surge and improving fundamentals.
It shows the market's cumulative response to the profit news, indicating sustained upward momentum.
Large Foreign Exchange Loss from Yuan-Dollar Swings The company incurred a large exchange loss due to fluctuations in the yuan against the US dollar. Excluding this, operating performance would have been even stronger. This is a real counterweight that partially offsets the profit surge and could pressure future earnings if currency volatility continues.
It presents a genuine risk factor that tempers the positive profit news and could affect future profitability.